Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1

July 23, 2024 David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Episode 73
73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
More Info
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1
Jul 23, 2024 Episode 73
David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado

Send us a Text Message.

Ready to revolutionize your lab work? Join us as we dive deep into bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech.

Discover how these tiny beads are making a massive impact on biotech research and development — for titer, glycan, and aggreation screening — and how this developability screening platform can enhance your antibody discovery, antibody engineering and lead optimization.

In this episode, you’ll learn:

  1. Speed and Simplicity: How bead-based assays offer unmatched throughput and ease of use, allowing you to analyze hundreds of samples in just a few steps.
  2. Versatile Applications: The diverse applications of bead-based assays in cell development, bioprocessing, and antibody discovery, helping streamline workflows and enhance innovation.
  3. Early Screening Advantages: The benefits of bead-based assays in early-stage process development, enabling quick decision-making with less detailed but rapid results.

Tune in to uncover how these assays can transform your biotech research and push the boundaries of what's possible!

Connect with Sebastian Giehring:

LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992

PAIA Biotech: https://www.paiabio.com

Next Steps:

Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Show Notes

Send us a Text Message.

Ready to revolutionize your lab work? Join us as we dive deep into bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech.

Discover how these tiny beads are making a massive impact on biotech research and development — for titer, glycan, and aggreation screening — and how this developability screening platform can enhance your antibody discovery, antibody engineering and lead optimization.

In this episode, you’ll learn:

  1. Speed and Simplicity: How bead-based assays offer unmatched throughput and ease of use, allowing you to analyze hundreds of samples in just a few steps.
  2. Versatile Applications: The diverse applications of bead-based assays in cell development, bioprocessing, and antibody discovery, helping streamline workflows and enhance innovation.
  3. Early Screening Advantages: The benefits of bead-based assays in early-stage process development, enabling quick decision-making with less detailed but rapid results.

Tune in to uncover how these assays can transform your biotech research and push the boundaries of what's possible!

Connect with Sebastian Giehring:

LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992

PAIA Biotech: https://www.paiabio.com

Next Steps:

Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com